To compare 12-month claims-derived health outcomes in amyloid PET-positive versus amyloid PET-negative individuals presenting with MCI and dementia in the entire study cohort of diverse Medicare beneficiaries.
To compare the proportions of participants with a hospitalization within 12 months, between amyloid PET-positive and amyloid PET-negative participants in the study, separately for patients with MCI and dementia.
To evaluate whether the association of amyloid PET result with 12-month hospitalizations is mediated by changes in each component of the composite management endpoint.
To describe the association of amyloid PET findings with changes in patient management and 12-month claims-derived health outcomes among Blacks/African Americans, Latinos/Hispanics and Whites/Caucasians presenting with MCI and dementia.
In each ethnoracial subgroup and level of impairment (MCI or dementia), to estimate the rate (proportion) of change between the pre-PET care plan and the 90-day implemented post-PET care plan, in a composite defined as change in one or more of the following items:
To describe the association of amyloid PET findings with changes in management and 12-month claims-derived health outcomes in individuals presenting with typical (progressive amnestic) versus atypical clinical presentations of MCI and AD dementia.
To assess and compare the proportion of change in the composite management endpoint in patients with “typical” (progressive amnestic) versus atypical clinical presentations of AD, separately for MCI and dementia
To assess the association between change in the composite management primary endpoint and the following potential predictors and interactions: